They also showed that DETANONOate (a nitric oxide donor) treatment reduces NF-κB DNA binding activity and Snail pathway inhibition, which mediates anti-metastatic properties in prostate cancer patients [105]. The gene discussed is SNAI1; the disease is prostate cancer.